CN110386932A - 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 - Google Patents

用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 Download PDF

Info

Publication number
CN110386932A
CN110386932A CN201810359447.6A CN201810359447A CN110386932A CN 110386932 A CN110386932 A CN 110386932A CN 201810359447 A CN201810359447 A CN 201810359447A CN 110386932 A CN110386932 A CN 110386932A
Authority
CN
China
Prior art keywords
optionally substituted
pyrrolo
methyl
pyridin
dihydrospiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810359447.6A
Other languages
English (en)
Chinese (zh)
Inventor
付健民
王尧德
孙跃
吴国胜
陆爱军
张双
R.古诺
T.吉尔默
M.卡斯滕
D.基尔什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acoslade Pharmaceutical Co Ltd
Original Assignee
Acoslade Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acoslade Pharmaceutical Co Ltd filed Critical Acoslade Pharmaceutical Co Ltd
Priority to CN201810359447.6A priority Critical patent/CN110386932A/zh
Priority to KR1020207033463A priority patent/KR20210027251A/ko
Priority to CA3096732A priority patent/CA3096732A1/en
Priority to PCT/CN2019/083104 priority patent/WO2019201283A1/en
Priority to BR112020021323-3A priority patent/BR112020021323A2/pt
Priority to MA052364A priority patent/MA52364A/fr
Priority to JP2021506031A priority patent/JP7366996B2/ja
Priority to SG11202010212RA priority patent/SG11202010212RA/en
Priority to AU2019254980A priority patent/AU2019254980B2/en
Priority to MX2020010942A priority patent/MX2020010942A/es
Priority to EP23202655.9A priority patent/EP4327877A3/en
Priority to CN201980040733.9A priority patent/CN112469720B/zh
Priority to EP19787882.0A priority patent/EP3784671B1/en
Publication of CN110386932A publication Critical patent/CN110386932A/zh
Priority to PH12020551717A priority patent/PH12020551717A1/en
Priority to US17/074,425 priority patent/US12187742B2/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201810359447.6A 2018-04-20 2018-04-20 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 Pending CN110386932A (zh)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CN201810359447.6A CN110386932A (zh) 2018-04-20 2018-04-20 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
SG11202010212RA SG11202010212RA (en) 2018-04-20 2019-04-17 Dual atm and dna-pk inhibitors for use in anti-tumor therapy
AU2019254980A AU2019254980B2 (en) 2018-04-20 2019-04-17 Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy
PCT/CN2019/083104 WO2019201283A1 (en) 2018-04-20 2019-04-17 Dual atm and dna-pk inhibitors for use in anti-tumor therapy
BR112020021323-3A BR112020021323A2 (pt) 2018-04-20 2019-04-17 Inibidores duplos de atm e dna-pk para uso em terapia antitumoral
MA052364A MA52364A (fr) 2018-04-20 2019-04-17 Inhibiteurs doubles d'atm et d'adn-pk pour une utilisation en thérapie antitumorale
JP2021506031A JP7366996B2 (ja) 2018-04-20 2019-04-17 抗腫瘍療法で使用するためのデュアルａｔｍ及びｄｎａ－ｐｋ阻害剤
KR1020207033463A KR20210027251A (ko) 2018-04-20 2019-04-17 항-종양 요법에서 사용하기 위한 이중 atm 및 dna-pk 억제제
CA3096732A CA3096732A1 (en) 2018-04-20 2019-04-17 Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2020010942A MX2020010942A (es) 2018-04-20 2019-04-17 Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
EP23202655.9A EP4327877A3 (en) 2018-04-20 2019-04-17 Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN201980040733.9A CN112469720B (zh) 2018-04-20 2019-04-17 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
EP19787882.0A EP3784671B1 (en) 2018-04-20 2019-04-17 Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020551717A PH12020551717A1 (en) 2018-04-20 2020-10-16 Dual atm and dna-pk inhibitors for use in anti-tumor therapy
US17/074,425 US12187742B2 (en) 2018-04-20 2020-10-19 Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810359447.6A CN110386932A (zh) 2018-04-20 2018-04-20 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂

Publications (1)

Publication Number Publication Date
CN110386932A true CN110386932A (zh) 2019-10-29

Family

ID=68283636

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810359447.6A Pending CN110386932A (zh) 2018-04-20 2018-04-20 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN201980040733.9A Active CN112469720B (zh) 2018-04-20 2019-04-17 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980040733.9A Active CN112469720B (zh) 2018-04-20 2019-04-17 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂

Country Status (10)

Country Link
US (1) US12187742B2 (enExample)
EP (2) EP4327877A3 (enExample)
JP (1) JP7366996B2 (enExample)
KR (1) KR20210027251A (enExample)
CN (2) CN110386932A (enExample)
BR (1) BR112020021323A2 (enExample)
CA (1) CA3096732A1 (enExample)
MA (1) MA52364A (enExample)
MX (1) MX2020010942A (enExample)
SG (1) SG11202010212RA (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021022078A1 (en) * 2019-07-30 2021-02-04 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
WO2021098734A1 (zh) * 2019-11-19 2021-05-27 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
WO2021098813A1 (zh) * 2019-11-22 2021-05-27 南京明德新药研发有限公司 作为dna-pk抑制剂的嘧啶并吡咯类螺环化合物及其衍生物
WO2021136462A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
WO2025247391A1 (en) * 2024-05-31 2025-12-04 Hutchmed Limited Novel pi3k and/or pikk inhibitors, antibody-drug conjugates comprising the same and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
WO2019201283A1 (en) 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN121152622A (zh) * 2023-03-06 2025-12-16 艾科思莱德控股开曼有限公司 治疗癌症的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523082A (ja) 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗菌活性および抗癌活性を有するヌクレオチド
NZ573049A (en) 2006-06-01 2010-08-27 Sanofi Aventis Spirocyclic nitriles as protease inhibitors
KR101504669B1 (ko) 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
US20110212053A1 (en) * 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
US8394818B2 (en) 2008-10-17 2013-03-12 Dana-Farber Cancer Institute, Inc. Soluble mTOR complexes and modulators thereof
JP2012528829A (ja) 2009-06-04 2012-11-15 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物
US9150577B2 (en) 2009-12-07 2015-10-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
KR20140014104A (ko) 2010-12-06 2014-02-05 피라말 엔터프라이지즈 리미티드 치환된 이미다조퀴놀린 유도체
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
AR089929A1 (es) 2012-02-10 2014-10-01 Actelion Pharmaceuticals Ltd Proceso para manufacturar un derivado de naftiridina
SI2861595T1 (sl) 2012-06-13 2017-04-26 Incyte Holdings Corporation Substituirane triciklične spojine kot inhibitorji fgfr
CN103936762B (zh) * 2013-01-17 2016-02-24 上海汇伦生命科技有限公司 吗啉并喹啉类化合物，其制备方法和用途
CN103880844A (zh) * 2014-04-09 2014-06-25 彭正中 一种喹啉酮类新化合物及其制备方法与用途
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
CN105461712B (zh) * 2014-06-17 2019-01-29 上海嘉坦医药科技有限公司 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
KR102495840B1 (ko) * 2014-06-17 2023-02-03 치아타이 티안큉 파마수티컬 그룹 주식회사 PI3K 억제제로 사용되는 피리디노[1,2-a]피리미돈 유사체
RU2658912C1 (ru) * 2014-06-17 2018-06-26 Шанхай Цзя Тань Фарматек Ко. Лтд. АНАЛОГ ПИРИДИНО[1,2-А]ПИРИМИДОНА, ИСПОЛЬЗУЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА mTOR/PI3K
CN105461711B (zh) * 2014-06-17 2018-11-06 正大天晴药业集团股份有限公司 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
EP3194369A4 (en) 2014-09-17 2018-02-28 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
HUE054745T2 (hu) 2015-04-02 2021-09-28 Merck Patent Gmbh Imidazolonilkinolinok és alkalmazásuk ATM-kináz-inhibitorokként
WO2016186453A1 (en) 2015-05-20 2016-11-24 Kainos Medicine, Inc. Quinoline derivatives as bromodomain inhibitors
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP3405465B1 (en) 2016-01-20 2021-10-13 Biogen MA Inc. Irak4 inhibiting agents
WO2017162611A1 (en) * 2016-03-21 2017-09-28 Astrazeneca Ab Quinoline-3-carboxamide compounds and their use in treating cancer
TWI696615B (zh) 2016-05-05 2020-06-21 瑞士商伊蘭科動物健康公司 雜芳基-1,2,4-三唑及雜芳基-三唑化合物
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN112771045B (zh) * 2018-09-30 2022-04-19 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用
CN119684291A (zh) 2019-07-30 2025-03-25 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021022078A1 (en) * 2019-07-30 2021-02-04 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
WO2021098734A1 (zh) * 2019-11-19 2021-05-27 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
CN114746421A (zh) * 2019-11-19 2022-07-12 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
WO2021098813A1 (zh) * 2019-11-22 2021-05-27 南京明德新药研发有限公司 作为dna-pk抑制剂的嘧啶并吡咯类螺环化合物及其衍生物
TWI768550B (zh) * 2019-11-22 2022-06-21 大陸商南京明德新藥研發有限公司 作為dna-pk抑制劑的嘧啶并吡咯類螺環化合物及其衍生物
CN114728978A (zh) * 2019-11-22 2022-07-08 南京明德新药研发有限公司 作为dna-pk抑制剂的嘧啶并吡咯类螺环化合物及其衍生物
WO2021136462A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN115380031A (zh) * 2020-03-30 2022-11-22 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
WO2025247391A1 (en) * 2024-05-31 2025-12-04 Hutchmed Limited Novel pi3k and/or pikk inhibitors, antibody-drug conjugates comprising the same and uses thereof

Also Published As

Publication number Publication date
AU2019254980A1 (en) 2020-12-03
JP7366996B2 (ja) 2023-10-23
EP4327877A3 (en) 2024-04-24
US20220315606A1 (en) 2022-10-06
EP4327877A2 (en) 2024-02-28
US12187742B2 (en) 2025-01-07
CA3096732A1 (en) 2019-10-24
CN112469720A (zh) 2021-03-09
JP2021522316A (ja) 2021-08-30
CN112469720B (zh) 2024-03-29
MA52364A (fr) 2021-03-03
BR112020021323A2 (pt) 2021-01-19
SG11202010212RA (en) 2020-11-27
MX2020010942A (es) 2021-01-15
EP3784671A1 (en) 2021-03-03
KR20210027251A (ko) 2021-03-10
EP3784671B1 (en) 2023-10-11
EP3784671A4 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
CN110386932A (zh) 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2019201283A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
JP7595959B2 (ja) 抗腫瘍療法において使用するための二重ａｔｍ及びｄｎａ－ｐｋ阻害剤
US11117885B2 (en) Compounds having estrogen receptor alpha degradation activity and uses thereof
JP6817207B2 (ja) ハンチントンタンパク質のイメージング用プローブ
TW201726623A (zh) 作為免疫調節劑之雜環化合物
WO2014151630A2 (en) Compounds and compositions for the treatment of parasitic diseases
ES2985416T3 (es) Nuevos compuestos potentes y selectivos como moduladores del receptor de serotonina 1B
TWI887852B (zh) 大環雜環類化合物作為egfr抑制劑的製備及其應用
CN112300159A (zh) 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
RU2800756C1 (ru) Двойные ингибиторы atm и dna-pk для применения в противоопухолевой терапии
HK40047614B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
HK40047614A (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
HK40072201B (zh) 用於抗肿瘤疗法中的双重atm和dna-pk抑制剂
TW202442224A (zh) Fgfr2與fgfr3之抑制劑及其用途
TW202530233A (zh) 嘧啶並噻喃酮kras突變蛋白抑制劑的製備及其應用
HK40072201A (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
TW202312995A (zh) 氮雜芳基化合物、其製備方法及應用
HK40058838A (en) Novel compounds having estrogen receptor alpha degradation activity and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191029